{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:26:57Z","timestamp":1792794417793,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Tokyo Metropolitan Hospital Organization","award":["R030403027"],"award-info":[{"award-number":["R030403027"]}],"id":[{"id":"https:\/\/ror.org\/04y0s1771","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intensity-modulated radiation therapy (IMRT) has been increasingly used as a new radiation modality for unresectable non-small cell lung cancer (NSCLC). The risk factors for radiation pneumonitis (RP) during consolidation durvalumab following concurrent chemoradiotherapy (CCRT) using IMRT have not been thoroughly investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study analyzed medical record data from consecutive patients diagnosed with NSCLC who underwent CCRT and consolidation durvalumab at our institution between April 2018 and September 2022. Since we adopted IMRT for the treatment of NSCLC in April 2020, these patients were categorized into two groups: those treated with IMRT after April 2020 and those treated with three-dimensional conformal radiotherapy (3D-CRT) before April 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 31 patients underwent IMRT (the IMRT group), while 25 patients underwent 3D-CRT (the 3D-CRT group). In both groups, the total dose was 60\u00a0Gy in 30 fractions. The cumulative incidence of \u2265 grade 2 RP at 12\u00a0months was significantly lower in the IMRT group than in the 3D-CRT group (27.0% vs. 64.0%, hazard ratio [HR]: 0.338, 95% confidence interval [CI]: 0.144\u20130.793, p\u00a0=\u00a00.013). In the multivariable analysis, V20 (\u2265 25.6%, HR: 2.706, 95% CI: 1.168\u20136.269, p\u00a0=\u00a00.020) and radiotherapy technique (IMRT, HR: 0.414, 95% CI: 0.172\u20130.994, p\u00a0=\u00a00.048) were identified as significant risk factors for \u2265 grade 2 RP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IMRT is associated with a lower rate of \u2265 grade 2 RP in patients with NSCLC who received CCRT followed by durvalumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyad158","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T16:42:08Z","timestamp":1698252128000},"page":"312-318","source":"Crossref","is-referenced-by-count":12,"title":["A comparison of the incidence of \u2265 grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8115-4073","authenticated-orcid":false,"given":"Masahiro","family":"Masuo","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Shinohara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Maruta","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Chonabayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"},{"name":"Department of Respiratory Medicine, Kashiwa City Hospital , Chiba 277-0825 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"},{"name":"Department of Respiratory Medicine, Tokyo Medical and Dental University , Tokyo 113-8519 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhei","family":"Matumoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Machitori","sequence":"additional","affiliation":[{"name":"Department of Radiology, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Bokutoh Hospital , Tokyo 130-1022 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"2024031106210561300_ref1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ijrobp.2003.09.086","article-title":"Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer","volume":"58","author":"Murshed","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024031106210561300_ref3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"2024031106210561300_ref4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"2024031106210561300_ref5","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0360-3016(99)00183-2","article-title":"Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)","volume":"45","author":"Graham","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0360-3016(02)03807-5","article-title":"Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer","volume":"55","author":"Tsujino","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.ijrobp.2003.09.085","article-title":"Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer","volume":"58","author":"Liu","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ijrobp.2008.02.057","article-title":"Irradiation of varying volumes of rat lung to same mean lung dose: a little to a lot or a lot to a little?","volume":"71","author":"Semenenko","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ijrobp.2010.12.073","article-title":"Intensity-modulated radiotherapy might increase pneumonitis risk relative to three-dimensional conformal radiotherapy in patients receiving combined chemotherapy and radiotherapy: a modeling study of dose dumping","volume":"80","author":"Vogelius","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","article-title":"Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis","volume":"85","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref12","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"2024031106210561300_ref13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024031106210561300_ref14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2020.01.008","article-title":"Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study","volume":"141","author":"Niho","year":"2020","journal-title":"Lung Cancer"},{"key":"2024031106210561300_ref15","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.jtho.2018.08.350","article-title":"MA05.02 PACIFIC subgroup analysis: pneumonitis in stage III, Unresectable NSCLC patients treated with Durvalumab vs. placebo after CRT","volume":"13","author":"Vansteenkiste","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024031106210561300_ref16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s10637-020-00917-2","article-title":"Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer","volume":"38","author":"Inoue","year":"2020","journal-title":"Invest New Drugs"},{"key":"2024031106210561300_ref17","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2021.08.019","article-title":"Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005\/CRIMSON)","volume":"161","author":"Saito","year":"2021","journal-title":"Lung Cancer"},{"key":"2024031106210561300_ref18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","article-title":"Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"146","author":"Jung","year":"2020","journal-title":"Lung Cancer"},{"key":"2024031106210561300_ref19","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.21037\/jtd-20-1792","article-title":"Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer","volume":"12","author":"Hassanzadeh","year":"2020","journal-title":"J Thorac Dis"},{"key":"2024031106210561300_ref20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13014-021-01979-z","article-title":"Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer","volume":"17","author":"Mayahara","year":"2022","journal-title":"Radiat Oncol"},{"key":"2024031106210561300_ref21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2022.10.002","article-title":"Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer","volume":"176","author":"Xu","year":"2022","journal-title":"Radiother Oncol"},{"key":"2024031106210561300_ref22","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2006.12.031","article-title":"Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"68","author":"Yom","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024031106210561300_ref24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","article-title":"Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent Chemoradiotherapy and consolidation Durvalumab","volume":"22","author":"Shintani","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2024031106210561300_ref25","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/jjco\/hyab163","article-title":"Potential benefits of volumetric modulated arc therapy to reduce the incidence of \u2265 grade 2 radiation pneumonitis in radiotherapy for locally advanced non-small cell lung cancer patients","volume":"51","author":"Imano","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2024031106210561300_ref26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1097\/JTO.0000000000000346","article-title":"Intensity-modulated radiotherapy for lung cancer: current status and future developments","volume":"9","author":"Chan","year":"2014","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer"},{"key":"2024031106210561300_ref27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.radonc.2021.05.016","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study","volume":"160","author":"Tsukita","year":"2021","journal-title":"Radiother Oncol"},{"key":"2024031106210561300_ref28","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41598-021-04601-0","article-title":"Risk factors for radiation pneumonitis after rotating gantry intensity-modulated radiation therapy for lung cancer","volume":"12","author":"Tatsuno","year":"2022","journal-title":"Sci Rep"},{"key":"2024031106210561300_ref29","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/1097-0142(19820915)50:6<1091::AID-CNCR2820500612>3.0.CO;2-0","article-title":"Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by the radiation therapy oncology group","volume":"50","author":"Perez","year":"1982","journal-title":"Cancer"},{"key":"2024031106210561300_ref30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13014-016-0698-3","article-title":"Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)","volume":"11","author":"Li","year":"2016","journal-title":"Radiat Oncol"},{"key":"2024031106210561300_ref31","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jtho.2018.04.011","article-title":"Exploring radiotherapy targeting strategy and dose: a pooled analysis of cooperative group trials of combined modality therapy for stage III NSCLC","volume":"13","author":"Schild","year":"2018","journal-title":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer."},{"key":"2024031106210561300_ref32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s10147-014-0718-y","article-title":"Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective","volume":"19","author":"Nakamura","year":"2014","journal-title":"Int J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/3\/312\/56912442\/hyad158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/3\/312\/56912442\/hyad158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T02:25:47Z","timestamp":1710123947000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/3\/312\/7450932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,11,25]]},"published-print":{"date-parts":[[2024,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad158","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,11,25]]}}}